Clinical and morphological features in patients with advanced endometrial cancer treated with immunotargeting therapy

Background . Endometrial cancer (EC) is one of the most significant oncogynecological problems. The main mortality cause in this disease, as in the case of other malignant neoplasms, is the tumor progression. The presence of mutations associated with mismatch repair-deficient is of great prognostic...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Opukholi zhenskoĭ reproduktivnoĭ sistemy 2023-08, Vol.19 (2), p.109-118
Hauptverfasser: Kolomiets, L. A., Stakheeva, M. N., Churuksaeva, O. N., Villert, A. B., Chernyshova, A. L., Sisakyan, V. G., Lots, I. Yu, Chernorubashkina, N. M., Zhurman, V. N., Grechkina, A. A., Aleksandrova, E. N., Musaeva, N. E., Diduk, O. V., Bulygina, N. A., Pyatina, D. A., Obraz, I. L., Krechetova, A. V., Danilova, M. A., Khodzhakhova, M. A., Malsteva, A. A., Ermak, N. A.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Background . Endometrial cancer (EC) is one of the most significant oncogynecological problems. The main mortality cause in this disease, as in the case of other malignant neoplasms, is the tumor progression. The presence of mutations associated with mismatch repair-deficient is of great prognostic importance. Immunotargeting therapy (ITT), lenvatinib in combination with pembrolizumab, seems to be the most effective solution in the second line treatment of advanced EC without microsatellite instability. At the same time, the group of such patients is heterogeneous in terms of progression-free survival (PFS) on ITT. So that it determines the continuing need to search for reliable parameters steadily associated with the PFS duration in this type of treatment. Aim . To analyze the clinical and morphological features in patients with advanced EC depending on the PFS duration on ITT. Materials and methods. The study included data on patients ( n = 36) with advanced EC who received ITT in oncological dispensaries in Siberia and the Russian Far East. The overall patients’ group was analyzed using the Kaplan-Meier method. PFS was defined as the time from the ITT initiation until progression or death against the background of treatment. The influence of the selected factors (clinical and morphological parameters, treatment features, and adverse events) on PFS was assessed using a log-rank criterion. The study participants were then divided into 2 subgroups (15 women and 9 women) according to median PFS. Mann–Whitney tests for independent samples (quantitative measures), and Fisher’s tests (qualitative measures) were used to identify significant differences in comparison subgroups for the selected factors. Differences were considered statistically significant when the significance level was reached ( p
ISSN:1994-4098
1999-8627
DOI:10.17650/1994-4098-2023-19-2-109-118